VA's $1.04B Pharmaceutical Prime Vendor Contract Awarded to McKesson Corporation for FY2025
Contract Overview
Contract Amount: $1,043,484,625 ($1.0B)
Contractor: Mckesson Corporation
Awarding Agency: Department of Veterans Affairs
Start Date: 2025-05-01
End Date: 2025-05-30
Sector: Healthcare
Official Description: EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2025 MAY
Plain-Language Summary
Department of Veterans Affairs obligated $1.04 billion to MCKESSON CORPORATION for work described as: EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2025 MAY Key points: 1. The Department of Veterans Affairs (VA) awarded a significant $1.04 billion contract for pharmaceutical prime vendor services. 2. McKesson Corporation, a major player in pharmaceutical distribution, secured this substantial contract. 3. The contract covers a one-month period (May 2025), indicating a potential for recurring or follow-on awards. 4. This award highlights the critical role of pharmaceutical supply chain management within the VA. 5. The scale of the award suggests a high volume of pharmaceutical needs for veterans.
Value Assessment
Rating: good
The contract value of $1.04 billion for a single month is substantial, reflecting the VA's extensive pharmaceutical needs. Benchmarking against similar large-scale pharmaceutical distribution contracts would be necessary for a precise value assessment, but the amount suggests competitive pricing for the volume and services provided.
Cost Per Unit: N/A
Competition Analysis
Competition Level: unknown
The contract type is a Delivery Order, but the specific award mechanism (e.g., competitive bid, sole-source) is not detailed. If awarded competitively, it likely resulted in favorable pricing for the VA. If sole-source, further justification would be needed to ensure optimal price discovery.
Taxpayer Impact: The VA's ability to secure pharmaceuticals at competitive prices through this contract directly impacts taxpayer funds allocated to veteran healthcare.
Public Impact
Ensures timely access to essential medications for veterans nationwide. Supports the operational readiness of VA healthcare facilities. Contributes to the overall health and well-being of the veteran population. Maintains a stable and reliable pharmaceutical supply chain for critical medical needs.
Waste & Efficiency Indicators
Waste Risk Score: 50 / 10
Warning Flags
- Lack of clarity on the competitive nature of the award.
- Potential for price fluctuations in subsequent delivery orders.
- Dependence on a single vendor for a critical supply chain.
Positive Signals
- Significant contract value indicates substantial demand and potential for economies of scale.
- Award to a known, established vendor suggests reliability.
- Focus on pharmaceutical supply chain is crucial for healthcare delivery.
Sector Analysis
The healthcare sector, particularly pharmaceutical distribution, is a critical component of government spending. Contracts like this support the vast network of healthcare providers and ensure the availability of essential medicines, with benchmarks often tied to market rates and volume discounts.
Small Business Impact
The data does not provide information on small business participation in this contract. Large prime vendor contracts often involve complex supply chains where subcontracting opportunities for small businesses may exist, but this is not explicitly stated.
Oversight & Accountability
Oversight of this contract would involve monitoring McKesson Corporation's performance in terms of delivery timeliness, product quality, and adherence to contractual terms. The VA's procurement and contract management teams are responsible for ensuring accountability and value for taxpayer money.
Related Government Programs
- Department of Veterans Affairs Contracting
- Department of Veterans Affairs Programs
Risk Flags
- Potential for price increases in future delivery orders.
- Dependence on a single large supplier.
- Lack of transparency regarding the competitive bidding process.
- Complexity of managing a nationwide pharmaceutical supply chain.
Tags
department-of-veterans-affairs, delivery-order, billion-dollar
Frequently Asked Questions
What is this federal contract paying for?
Department of Veterans Affairs awarded $1.04 billion to MCKESSON CORPORATION. EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2025 MAY
Who is the contractor on this award?
The obligated recipient is MCKESSON CORPORATION.
Which agency awarded this contract?
Awarding agency: Department of Veterans Affairs (Department of Veterans Affairs).
What is the total obligated amount?
The obligated amount is $1.04 billion.
What is the period of performance?
Start: 2025-05-01. End: 2025-05-30.
What is the historical pricing trend for this Pharmaceutical Prime Vendor contract over previous years?
Analyzing historical pricing data for this PPV contract is crucial to determine if the current $1.04 billion award represents a fair market value or an escalation. Understanding past price adjustments, volume discounts, and any changes in service scope will provide context for the current award and help identify potential cost savings or areas of concern for future negotiations.
What specific performance metrics are being tracked to ensure McKesson Corporation meets the VA's pharmaceutical needs effectively?
Effective oversight requires clearly defined performance metrics, such as on-time delivery rates, order accuracy, drug availability, and temperature control compliance for sensitive medications. Tracking these metrics ensures McKesson is fulfilling its contractual obligations, directly impacting veteran care and preventing disruptions in pharmaceutical supply. Regular performance reviews are essential.
How does the VA mitigate risks associated with relying on a single large vendor for such a critical supply chain?
The VA likely employs risk mitigation strategies such as robust contract terms, performance incentives, and contingency planning. While McKesson is a major distributor, the VA may also maintain relationships with alternative suppliers or have emergency protocols in place to ensure continuity of care in case of unforeseen disruptions to McKesson's operations.
More Contracts from Mckesson Corporation
- Express Report: Pharmaceutical Prime Vendor (ppv)fy2026 November — $1.4B (Department of Veterans Affairs)
- Express Report: Pharmaceutical Prime Vendor (ppv)fy2026 October — $1.2B (Department of Veterans Affairs)
- Express Report: Pharmaceutical Prime Vendor (ppv)fy2025 September — $1.2B (Department of Veterans Affairs)
- Express Report: Pharmaceutical Prime Vendor (ppv)fy2025 July — $1.1B (Department of Veterans Affairs)
- Express Report: Pharmaceutical Prime Vendor (ppv)fy2026 December — $1.1B (Department of Veterans Affairs)
Other Department of Veterans Affairs Contracts
- CCN Region 3 Express Report — $5.2B (Optum Public Sector Solutions, Inc.)
- Express Report for FY22 Region 2 — $5.1B (Optum Public Sector Solutions, Inc.)
- Fiscal Year 2022 Express Report for Region 1 — $4.2B (Optum Public Sector Solutions, Inc.)
- Express Report for the Patient Centered Community Care (PC3) Contract — $3.3B (Triwest Healthcare Alliance Corp)
- CCN Region Three FY21 Express Report — $3.1B (Optum Public Sector Solutions, Inc.)